NCT04155645COMPLETEDanonymous

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects With Dyslipidemia With or Without Type 2 Diabetes

Sponsor

Source record

AstraZeneca

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

AZD8233 subcutaneous injection, Placebo

Indication / condition

AI-normalized

Dyslipidemia

Intervention

Source record

AZD8233 subcutaneous injection, Placebo

Source & freshness

Source record

NCT ID

NCT04155645

Original source

ClinicalTrials.gov

Source last updated

Jun 30, 2021

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04155645

Title

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects With Dyslipidemia With or Without Type 2 Diabetes

Sponsor

AstraZeneca

Status

COMPLETED

Phase

PHASE1

Condition raw

Dyslipidemia

Condition normalized

Dyslipidemia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

AZD8233 subcutaneous injection, Placebo

Target normalized

AZD8233 subcutaneous injection, Placebo

Interventions

AZD8233 subcutaneous injection, Placebo

Public preview

Source record

This is a Phase I study to assess the safety, tolerability and pharmacokinetics (PK), and pharmacodynamics (PD) of AZD8233, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD8233 in subjects with confirmed dyslipidemia with or without type 2 diabetes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects With Dyslipidemia With or Without Type 2 Diabetes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04155645

Status

COMPLETED

Phase

PHASE1

Sponsor

AstraZeneca

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 30, 2021

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04155645

Indication

Dyslipidemia

Modality

small molecule

Target

AZD8233 subcutaneous injection, Placebo

Intervention

AZD8233 subcutaneous injection, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.